IBT is a Swedish limited liability company, whose B shares are listed on Nasdaq Stockholm. Control of the company is via the Annual General Meeting, the Board of Directors, the CEO and senior management in accordance with the Companies Act, rules of procedure for the Board and instructions for the President and the Swedish Code of Corporate Governance. The Board is responsible for evaluating the targets and for continuously evaluating IBTs financial position and results as well as evaluating the operational management.

IBT will provide information about any divergences from the Swedish Code of Corporate Governance in the Corporate Governance Report.


General Meetings

Nomination Committee

Board of Directors

Management Team

Incentive Program

Internal Control

Articles of Association



General Meetings


Annual General Meeting 2021

May 4 2021

Nomination Committee 2021

Remuneration report – IBT 2020 ENG

IBT Announcement AGM 2021 ENG

IBT Voting form ENG

IBT Protokoll AGM 2021 (SWE)

Appendix 3 – Votes Cast AGM 2021 (SWE)

Annual General Meeting 2020

June 16, 2020

AGM Minutes 2020 (Swedish)

AGM Announcement 2020

Nomination Committee 2020

IBT Voting form (English)

Board report on the evaluation of remuneration 2019

Appendix 4 Boards proposal warrant program

Terms for warrants

Annual General Meeting 2019

May 6, 2019

IBT AGM Minutes (Swedish)

Press Release AGM (English)

Additional documents

AGM Announcement 2019

Nomination Committee

Proxy Form AGM

Board report on evaluation of remuneration 2018 

Auditors report on remuneration 2018 (Swedish)

Annual General Meeting 2018

May 15, 2018

IBT AGM Minutes (Swedish)

Press Release AGM (English)

Additional documents

AGM Announcement

Nomination Committee

Proxy form AGM

Board report on evaluation of remuneration 

AGM Modified Proposal

Extraordinary General Meeting

January 8, 2017

IBT EGM Minutes with Attachments (Swedish)

Press Release EGM (English)

Annual General Meeting 2017

May 4, 2017

IBT AGM Minutes (Swedish)

Press Release AGM (English)

Additional documents

AGM Announcement

Nomination Committee

Proxy form AGM

Proposal for Board Mandate Item 16


Nominating Committee 

The Annual General Meeting of 2021 decided that the Nomination Committee would be appointed as follows: The Chairman of the Board shall convene in terms of voting rights, the three largest shareholders in the Company, who each shall elect a representative to be a member of the Nomination Committee together with the Chairman of the Board.


In the establishment of the Nomination Committee, the ownership ratios as of June 30, 2021, shall determine the largest shareholders in terms of voting rights. The representative of the largest shareholder in the Nomination Committee at that time shall be the Chairman of the Nomination Committee.


If any of the three largest shareholders waives their right to appoint a member of the Nomination Committee, the next largest shareholder shall be allowed to appoint a member of the Nomination Committee. The names of the three owner’s representatives shall be published as soon as they have been appointed, but no later than six months before the Annual General Meeting 2022.


The Nominating Committee’s term of office extends until the new Nominating Committee is appointed.


The Nomination Committee has been formed in accordance with the decision of the Annual General Meeting and consists of, in addition to the Chairman of Infant Bacterial Therapeutics AB’s Board of Directors, Peter Rothschild, Per-Erik Andersson, appointed by the  company’s largest shareholder, in terms of voting rights,   Annwall & Rothschild Investments AB. Sebastian Jahreskog, who through Six Sis AG is the company’s second largest shareholder in terms of voting rights, and Jannis Kitsakis, appointed by the company’s third largest shareholder, in terms of voting rights, Fjärde AP-Fonden. All members of the Nomination Committee, except Peter Rothschild, is independent in relation to the company and company management.


The chairman of the Nomination Committee is Per-Erik Andersson since he is appointed by the largest shareholder, in terms of voting rights, in Infant Bacterial Therapeutics.


The Nomination Committee can be reached by Per-Erik Andersson, through e-mail to pea@pealaw.se, or by phone +46 (0) 70-537 98 92.


Incentive program

WARRANTS 2017/2022

On May 4, 2017, the Annual General Meeting decided on an incentive program by designated issue of warrants to a subsidiary established for this purpose.

The maximum number of warrants to be issued are 280 000.

The warrants were issued in June 2017 at market terms at a price determined by calculating market price at the time of issue using the Black & Scholes method of valuation.

The holder of warrants may during the period from April 3, 2022 through May 3, 2022, for each warrant subscribe for one and one tenth (1.1) new share in the company at a subscription price per share amounting to SEK 272,41.


For additional information, see the minutes from the Annual General Meeting May 4, 2017


Internal Control

IBT – Corp. Gov. Report 2018 (SWE)

IBT – Corp. Gov. Report 2017 (SWE)

IBT – Corp. Gov. Report 2016


Articles of Association

Articles of association for Infant Bacterial Therapeutics AB is available below in Swedish and English:

IBT – Bolagsordning / Articles of Association



The company’s auditors review the management and the CEO’s management of the company and the quality of the company’s financial reporting. The auditors also perform, on behalf of the Board, a review of the financial statements, including the year-end report, annual report review and review of a quarterly report.


The auditor’s report their audit to the shareholders through the audit report, which is presented at the Annual General Meeting.


The company’s auditor is Deloitte AB with Birgitta Lööf as auditor-in-charge.


Deloitte AB

Visiting address: Rehnsgatan 11, 113 79 Stockholm, Sweden

Telephone: +46 75 246 20 00